A Phase 2 interventional study of DWP-450 (Botulinum purified neurotoxin, Type A) in Glabellar Frown Lines, sponsored by Evolus, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-24.
Sponsored by Evolus, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective is to demonstrate the safety of multiple doses of DWP-450 purified Botulinum neurotoxin, Type A, in treatment of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in adult subjects.
Up to five hundred and thirty (530) subjects will be enrolled and injected with the study drug DWP-450 over the course of the 365 day study.
Subjects with moderate-to-severe glabellar lines at maximum frown on the 4 point Glabellar Line Scale (GLS, 0=none, 1= mild, 2=moderate, 3=severe), as judged by the investigator, will be eligible for injection with DWP-450.
Subjects may receive up to a maximum of 4 treatments and will be followed for 365 days from initial treatment.
Evolus, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DWP-450 (Botulinum toxin, Type A)
Biological: DWP-450 (Botulinum purified neurotoxin, Type A)
Botulinum toxin, Type A
Also known as: DWP-450
The Safety of Repeat DWP-450 Treatments - Proportion of Subjects With at Least One Adverse Event Over 1 Year
The primary safety analysis was the calculation of the proportion of subjects with at least one adverse event that occurred from Day 0 through Day 365.
Time frame: 365 days
Change From Baseline Glabellar Line Scale (GLS) Score at Rest and at Maximum Frown
Proportion of subjects with an improvement of 1 point or more (i.e., ≥1 point responders) on the GLS at rest at end of study/early termination: by Investigator assessment
Time frame: 365 days
| Milestone | Botulinum Toxin, Tyoe A |
|---|---|
| Started | 570 |
| Completed | 487 |
| Not completed | 83 |
| Withdrew: Pregnancy | 2 |
| Withdrew: Lost to follow-up | 37 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Scheduling conflicts | 15 |
| Withdrew: Moved away | 10 |
| Withdrew: Death | 1 |
| Withdrew: Various | 16 |
The primary safety analysis was the calculation of the proportion of subjects with at least one adverse event that occurred from Day 0 through Day 365.
| Participants | Botulinum Toxin, Tyoe A |
|---|---|
| The Safety of Repeat DWP-450 Treatments - Proportion of Subjects With at Least One Adverse Event Over 1 Year | 235 |
Proportion of subjects with an improvement of 1 point or more (i.e., ≥1 point responders) on the GLS at rest at end of study/early termination: by Investigator assessment
| Participants | Botulinum Toxin, Type A |
|---|---|
| Change From Baseline Glabellar Line Scale (GLS) Score at Rest and at Maximum Frown | 355 |
Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Botulinum Toxin, Type A | — | 7/570 (1.2%) | 228/570 (40%) |
| Event | Botulinum Toxin, Type A |
|---|---|
| Carotid artery stenosisNervous system disorders | 1/570 |
| OverdoseInjury, poisoning and procedural complications | 1/570 |
| Small intestinal obstructionGastrointestinal disorders | 1/570 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/570 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/570 |
| AnxietyPsychiatric disorders | 1/570 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/570 |
| ColitisGastrointestinal disorders | 1/570 |
| Event | Botulinum Toxin, Type A |
|---|---|
| HeadacheNervous system disorders | 75/570 |
| Upper respiratory tract infectionInfections and infestations | 16/570 |
| SinusitisInfections and infestations | 14/570 |
| NasopharyngitisInfections and infestations | 13/570 |
| Urinary tract infectionInfections and infestations | 10/570 |
| HypertensionVascular disorders | 10/570 |
| ContusionInjury, poisoning and procedural complications | 9/570 |
| BronchitisInfections and infestations | 7/570 |
| Eyelid ptosisEye disorders | 7/570 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/570 |
| Age, Categorical(Participants) | Botulinum Toxin, Type A |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 519 |
| >=65 years | 51 |
| Sex: Female, Male(Participants) | Botulinum Toxin, Type A |
|---|---|
| Female | 510 |
| Male | 60 |
Plan to share: Undecided — Developing a plan
No publications or documents are linked to this record.
The record gives a start of May 2015, a primary completion of Oct 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2019, 2 years 4 months after primary completion. A results delay was requested in Feb 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prabotulinumtoxin A
Evolus, Inc.